Campath-1H + FK506 and Methylprednisolone for GVHD
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for
graft-versus-host disease caused by a donor stem cell transplant.
PURPOSE: This phase II trial is studying how well giving alemtuzumab together with tacrolimus
and methylprednisolone works in treating acute graft-versus-host disease in patients who have
undergone donor stem cell transplant.